WALTHAM, Mass. — Trinity, a global provider of technology-enabled commercialization solutions for the life sciences industry, has named Scott Evangelista as Chief Executive Officer, succeeding Leslie Orne, who is stepping down after three years as CEO and over 24 years with the company. Ms. Orne will transition to the role of Senior Advisor and will continue to serve on Trinity’s Board of Directors.
During her tenure, Ms. Orne played a pivotal role in guiding Trinity’s transformation from a consulting-focused organization to a global commercial solutions provider, while shaping a culture that emphasizes leadership development and innovation.
Mr. Evangelista, a seasoned pharmaceutical industry executive, brings more than 30 years of strategic leadership and operational expertise across consulting, contract research organizations (CROs), and biotechnology companies. He has served on Trinity’s Board of Advisors for the past three years, where he has contributed to organizational strategy, gained a deep understanding of the company’s culture, and helped chart its future direction.
“Trinity is focused on becoming the leader in technology-enabled services and products that help clients and employees effectively navigate today’s unprecedented pace of change,” said Matt Jennings, Executive Chairman of Trinity and Operating Partner of Kohlberg. “Scott is a proven leader who knows how to drive transformational growth in companies while preserving and leveraging what makes them exceptional: their people, their expertise, and a deep commitment to excellence. Through his leadership on the board of advisors, he’s demonstrated that he is ideally suited to lead Trinity into its next chapter of growth.”
Mr. Evangelista has extensive experience leading both high-growth startups and global organizations. He currently serves on the board of directors of Worldwide Clinical Trials and advises on growth and innovation as an Operating Executive of Kohlberg. He previously held senior leadership roles at IQVIA, Ironshore Pharmaceuticals, Deloitte, and founded Swiftwater Group. As CEO, he will focus on advancing Trinity’s mission to shape the future of life sciences commercialization by integrating human expertise with artificial intelligence.
“Trinity has long been recognized for its client-centric approach and expertise in driving commercialization excellence, and I am honored to join the company at this pivotal time in its journey,” said Mr. Evangelista. “I look forward to building on Trinity’s strong foundation by accelerating innovation, investing in data and technology, and advancing value for patients, clients, and employees. I cannot think of an organization better suited to help life sciences companies navigate a dynamic and complex market, and I am excited for what’s ahead.”
Mr. Jennings added: “I want to express our deep appreciation to Leslie for more than twenty years of dedicated service and enduring contributions to both Trinity and the life sciences industry. We look forward to continuing to benefit from her experience as she transitions to Senior Advisor.”
